journal article·2024-07-16

Biodegradable Microembolics with Nanografted Polyanions Enable High-Efficiency Drug Loading and Sustained Deep-Tumor Drug Penetration for Locoregional Chemoembolization Treatment

Yutao Ma, Zhihua Li, Yucheng Luo, Yao Chen, Le Ma, Xiaoya Liu, Jingyu Xiao, Man Huang, Yingnan Li, Hongliang Jiang, Meijuan Wang, Xiaoqian Wang, Jiangtao Li, Jian Kong, Peng Shi, Hanry Yu, Xingyu Jiang, Qiongyu Guo

ACS Nano· Volume 18· Issue 28
Publisher page

Abstract

Transarterial chemoembolization (TACE), the mainstay treatment of unresectable primary liver cancer that primarily employs nondegradable drug-loaded embolic agents to achieve synergistic vascular embolization and locoregional chemotherapy effects, suffers from an inferior drug burst behavior lacking long-term drug release controllability that severely limits the TACE efficacy. Here we developed gelatin-based drug-eluting microembolics grafted with nanosized poly(acrylic acid) serving as a biodegradable ion-exchange platform that leverages a counterion condensation effect to achieve high-efficiency electrostatic drug loading with electropositive drugs such as doxorubicin (i.e., drug loading capacity >34 mg/mL, encapsulation efficiency >98%, and loading time <10 min) and an enzymatic surface-erosion degradation pattern (∼2 months) to offer sustained locoregional pharmacokinetics with long-lasting deep-tumor retention capability for TACE treatment. The microembolics demonstrated facile microcatheter deliverability in a healthy porcine liver embolization model, superior tumor-killing capacity in a rabbit VX2 liver cancer embolization model, and stabilized extravascular drug penetration depth (>3 mm for 3 months) in a rabbit ear embolization model. Importantly, the microembolics finally exhibited vessel remodeling-induced permanent embolization with minimal inflammation responses after complete degradation. Such a biodegradable ion-exchange drug carrier provides an effective and versatile strategy for enhancing long-term therapeutic responses of various local chemotherapy treatments.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Multiple Myeloma Research and Treatments · Hepatocellular Carcinoma Treatment and Prognosis · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Shenzhen Key Laboratory of Smart Healthcare Engineering, Guangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China

Department of Biomedical Engineering, City University of Hong Kong, Kowloon, Hong Kong SAR 999077, China

Department of Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China

Department of Interventional Radiology, First Affiliated Hospital of Southern University of Science and Technology, Second Clinical Medical College of Jinan University, Shenzhen People’s Hospital, Shenzhen, Guangdong 518020, China

Shenzhen Research Institute, City University of Hong Kong, Shenzhen, Guangdong 518057, China

Mechanobiology Institute, National University of Singapore, 117411 Singapore

Department of Physiology, Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, 117593 Singapore

Singapore-MIT Alliance for Research and Technology, 138602 Singapore

Funding

National Key Research and Development Program of China · Science, Technology and Innovation Commission of Shenzhen Municipality · National Natural Science Foundation of China · Guangdong Research Fund · Shenzhen Key Laboratory of Smart Healthcare Engineering · Guangdong Provincial Key Laboratory of Advanced Biomaterials

References (57)

Show source-provided references
1. 10.1038/s41572-020-00240-310.1038/s41572-020-00240-3 ↗
2. 10.1016/j.bbcan.2019.18831410.1016/j.bbcan.2019.188314 ↗
3. 10.1038/nrclinonc.2014.12210.1038/nrclinonc.2014.122 ↗
4. 10.1038/s41575-019-0186-y10.1038/s41575-019-0186-y ↗
5. 10.1097/HEP.000000000000046610.1097/HEP.0000000000000466 ↗
6. 10.1016/j.ctrv.2018.11.00210.1016/j.ctrv.2018.11.002 ↗
7. 10.1080/17425247.2021.183585810.1080/17425247.2021.1835858 ↗
8. 10.1016/j.jimed.2020.07.00310.1016/j.jimed.2020.07.003 ↗
9. 10.18528/ijgii21004510.18528/ijgii210045 ↗
10. 10.1016/j.jhep.2011.03.02410.1016/j.jhep.2011.03.024 ↗
11. 10.1016/j.jvir.2017.01.01810.1016/j.jvir.2017.01.018 ↗
12. 10.1002/advs.20220619510.1002/advs.202206195 ↗
13. 10.1016/j.jconrel.2017.07.01610.1016/j.jconrel.2017.07.016 ↗
14. 10.18632/oncotarget.1999710.18632/oncotarget.19997 ↗
15. 10.1177/088532821774667410.1177/0885328217746674 ↗
16. 10.1080/09205063.2014.98224210.1080/09205063.2014.982242 ↗
17. 10.1021/acsbiomaterials.8b0063510.1021/acsbiomaterials.8b00635 ↗
18. 10.1080/09205063.2021.199047210.1080/09205063.2021.1990472 ↗
19. 10.1080/17425247.2017.129503610.1080/17425247.2017.1295036 ↗
20. 10.1016/j.tibtech.2020.04.00610.1016/j.tibtech.2020.04.006 ↗
21. 10.1021/acs.biomac.7b0147910.1021/acs.biomac.7b01479 ↗
22. 10.1080/1539445X.2018.143555210.1080/1539445X.2018.1435552 ↗
23. 10.7150/thno.2737910.7150/thno.27379 ↗
24. 10.1016/j.ijbiomac.2019.11.12210.1016/j.ijbiomac.2019.11.122 ↗
25. 10.1016/j.ijbiomac.2019.10.02610.1016/j.ijbiomac.2019.10.026 ↗
26. 10.1016/j.actbio.2013.02.01710.1016/j.actbio.2013.02.017 ↗
27. 10.1080/0265204070133921310.1080/02652040701339213 ↗
28. 10.1002/app.4573110.1002/app.45731 ↗
29. 10.1002/adhm.20160129110.1002/adhm.201601291 ↗
30. 10.1007/s10856-006-0040-y10.1007/s10856-006-0040-y ↗
31. 10.1021/accountsmr.2c0014710.1021/accountsmr.2c00147 ↗
32. 10.1088/2516-1091/ab6c7d10.1088/2516-1091/ab6c7d ↗
33. 10.1016/j.jvir.2009.06.00510.1016/j.jvir.2009.06.005 ↗
34. 10.1007/s00270-019-02224-710.1007/s00270-019-02224-7 ↗
35. 10.1103/PhysRevE.65.05150210.1103/PhysRevE.65.051502 ↗
36. 10.1016/j.elecom.2011.11.02410.1016/j.elecom.2011.11.024 ↗
37. 10.1002/adhm.20210228110.1002/adhm.202102281 ↗
38. 10.1016/j.jceh.2019.01.00410.1016/j.jceh.2019.01.004 ↗
39. 10.1038/s41571-018-0073-410.1038/s41571-018-0073-4 ↗
40. 10.3748/wjg.v24.i2.16110.3748/wjg.v24.i2.161 ↗
41. 10.1097/01.RVI.0000195323.46152.B310.1097/01.RVI.0000195323.46152.B3 ↗
42. 10.2217/fon-2018-013610.2217/fon-2018-0136 ↗
43. 10.1016/j.ejps.2019.05.02110.1016/j.ejps.2019.05.021 ↗
44. 10.1007/s00270-010-9794-110.1007/s00270-010-9794-1 ↗
45. 10.1053/j.tvir.2009.09.00710.1053/j.tvir.2009.09.007 ↗
46. 10.1007/s00270-010-0012-y10.1007/s00270-010-0012-y ↗
47. 10.1002/adma.20200261110.1002/adma.202002611 ↗
48. 10.1016/j.jvir.2022.07.01110.1016/j.jvir.2022.07.011 ↗
49. 10.1007/s13346-021-00985-810.1007/s13346-021-00985-8 ↗
50. 10.1097/01.RVI.0000228416.21560.7F10.1097/01.RVI.0000228416.21560.7F ↗
51. 10.1016/j.jvir.2010.02.04210.1016/j.jvir.2010.02.042 ↗
52. 10.1002/adma.20190107110.1002/adma.201901071 ↗
53. 10.1002/adfm.20180184010.1002/adfm.201801840 ↗
54. 10.1016/j.addr.2022.11445010.1016/j.addr.2022.114450 ↗
55. 10.1002/advs.20200258910.1002/advs.202002589 ↗
56. 10.1016/j.biomaterials.2020.11985510.1016/j.biomaterials.2020.119855 ↗
57. 10.1016/j.biomaterials.2022.12142610.1016/j.biomaterials.2022.121426 ↗